North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
Robert R McWilliamsNathan R FosterMichelle R MahoneyThomas C SmyrkJoseph A MurrayMatthew M AmesL Elise HorvathDaniel J SchneiderTimothy J HobdayAminah JatoiJeffrey P MeyersMatthew P GoetzPublished in: Cancer (2017)
UGT1A1 genotype-directed dosing (gCAPIRINOX) appears to be feasible with favorable rates of hematologic toxicity compared with prior 3-drug studies in unselected patients. Larger studies would be needed to determine the regimen's comparability to oxaliplatin and capecitabine (CapeOx) alone or if response/toxicity differs among patients with different UGT1A1 genotypes. Cancer 2017;123:3494-501. © 2017 American Cancer Society.
Keyphrases
- papillary thyroid
- small bowel
- end stage renal disease
- locally advanced
- squamous cell
- ejection fraction
- oxidative stress
- chronic kidney disease
- squamous cell carcinoma
- newly diagnosed
- phase ii study
- prognostic factors
- case control
- emergency department
- lymph node metastasis
- metastatic breast cancer
- peritoneal dialysis
- phase iii
- young adults
- childhood cancer
- rectal cancer
- patient reported